Macquarie Group Ltd. Has $326,000 Position in American Renal Associates Holdings Inc (ARA)

Macquarie Group Ltd. increased its position in shares of American Renal Associates Holdings Inc (NYSE:ARA) by 1,867.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,700 shares of the company’s stock after buying an additional 19,648 shares during the period. Macquarie Group Ltd. owned 0.06% of American Renal Associates worth $326,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in American Renal Associates by 69.9% during the second quarter. Bank of America Corp DE now owns 113,109 shares of the company’s stock worth $1,784,000 after buying an additional 46,522 shares during the last quarter. Alambic Investment Management L.P. raised its stake in American Renal Associates by 12.1% during the second quarter. Alambic Investment Management L.P. now owns 63,291 shares of the company’s stock worth $998,000 after buying an additional 6,851 shares during the last quarter. OppenheimerFunds Inc. raised its stake in American Renal Associates by 44.3% during the second quarter. OppenheimerFunds Inc. now owns 403,351 shares of the company’s stock worth $6,361,000 after buying an additional 123,773 shares during the last quarter. Renaissance Technologies LLC raised its stake in American Renal Associates by 111.2% during the second quarter. Renaissance Technologies LLC now owns 347,500 shares of the company’s stock worth $5,480,000 after buying an additional 183,000 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in American Renal Associates by 937.3% during the second quarter. Citadel Advisors LLC now owns 128,282 shares of the company’s stock worth $2,023,000 after buying an additional 115,915 shares during the last quarter. 93.25% of the stock is owned by institutional investors and hedge funds.

NYSE:ARA opened at $20.47 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.07 and a debt-to-equity ratio of 5.30. The firm has a market capitalization of $702.91 million, a price-to-earnings ratio of 33.56, a P/E/G ratio of 3.83 and a beta of 2.51. American Renal Associates Holdings Inc has a 12 month low of $9.91 and a 12 month high of $24.07.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. The business had revenue of $217.18 million during the quarter, compared to analysts’ expectations of $203.70 million. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. As a group, research analysts anticipate that American Renal Associates Holdings Inc will post 0.6 EPS for the current year.

A number of brokerages recently weighed in on ARA. Bank of America lifted their target price on shares of American Renal Associates from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Leerink Swann raised shares of American Renal Associates from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $22.00 to $26.00 in a research note on Thursday, August 23rd. Zacks Investment Research raised shares of American Renal Associates from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. SunTrust Banks reissued a “buy” rating and set a $25.00 target price on shares of American Renal Associates in a research note on Thursday, August 9th. Finally, ValuEngine raised shares of American Renal Associates from a “hold” rating to a “buy” rating in a research note on Friday, August 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. American Renal Associates presently has a consensus rating of “Buy” and an average price target of $20.80.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: Asset Allocation

Institutional Ownership by Quarter for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply